Meeting
2018 Gastrointestinal Cancers Symposium
First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.
Authors
Pat Gulhati
University of Texas MD Anderson Cancer Center, Houston, TX
Pat Gulhati , Laura Prakash , Matthew H. G. Katz , Xuemei Wang , Milind M. Javle , Rachna T. Shroff , David R. Fogelman , Jeffrey Edwin Lee , Ching-Wei David Tzeng , Jeffrey H Lee , Brian Weston , Eric P. Tamm , Priya Bhosale , Eugene Jon Koay , Anirban Maitra , Huamin Wang , Robert A. Wolff , Gauri R. Varadhachary
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 369)
DOI
10.1200/JCO.2018.36.4_suppl.369
Abstract #
369
Poster Bd #
H6
Abstract Disclosures
Similar Posters
First Author: Evan Justin Walker
Poster
2018 Gastrointestinal Cancers Symposium
The relationship between dose to skeletal muscle area ratio and gemcitabine nab-paclitaxel toxicity in pancreatic ductal adenocarcinoma.
First Author: Rachel Wong
Poster
2017 Gastrointestinal Cancers Symposium
Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Hui-Li Wong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma.
First Author: Andrea Pretta